Skip to main content
The Markets by Proactive
Go to Proactive Australia

Pharma & Biotech

NetScientific gives further backing to PDS Biotechnology

The funding from this offering will support the continued development of PDS's lead HPV oncology candidate (PDS0101) in the three Phase II trials currently underway.

NetScientific PLC (LON:NSCI) said its portfolio company, PDS Biotechnology Corporation (NASDAQ:PDSB), has closed its underwritten public offering of shares.

The shares were offered at US$8.50 a pop. NetScientific participated in the share offering, buying 60,000 shares, which means its stake in PDS is about 4.72%.

The gross proceeds to PDS Biotech from this offering, before deducting underwriting discounts, commissions and other offering expenses were about US$51.7mln.

READ NetScientific follows its money as investee company announces plans to raise US$45mln